drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (iNKT cells)
drug_description
Allogeneic unmodified invariant natural killer T (iNKT) cell therapy; iNKT cells recognize glycolipid antigens via CD1d, secrete Th1 cytokines, and activate NK cells, CD8 T cells, and macrophages to kill tumor and remodel the tumor microenvironment.
nci_thesaurus_concept_id
C178501
nci_thesaurus_preferred_term
Allogeneic Invariant Natural Killer T-cells agenT-797
nci_thesaurus_definition
A preparation of allogeneic, off-the shelf, natural killer T-cells (NKTs) expressing an invariant (alpha, beta) T-cell receptor (iNKTs), with potential immunomodulating and antineoplastic activities. Upon administration of allogeneic iNKT agenT-797, the invariant T-cell receptor (TCR) and natural-killer group 2, member D receptor (NKG2D; KLRK1; natural killer cell activating receptor group 2D) expressed by these cells recognize CD1d-restricted lipid ligands and stress ligands, which are expressed on certain tumor cells. These receptor-ligand interactions may induce the secretion of large amounts of various pro-inflammatory cytokines, including interferon gamma (IFN-g), and activate the immune system against tumor cells. Additionally, iNKTs directly target and lyse tumor cells.
drug_category
CULTURED CELLS
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic, unmodified invariant NKT cells that recognize CD1d-presented glycolipid antigens and stress ligands via invariant TCR and NKG2D, secrete Th1 cytokines (e.g., IFN-γ), activate NK cells, CD8 T cells, and macrophages, and directly lyse tumor cells to remodel the tumor microenvironment.
drug_name
AgenT-797
nct_id_drug_ref
NCT06251973